| Customization: | Available |
|---|---|
| Application: | Internal Medicine |
| Usage Mode: | I.M./I.V. |
|
Still deciding? Get samples of US$ 5/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| 1.Active ingredient | Ampicillin Sodium |
| 2.Dosage | 250mg, 500mg, 1gram |
| 3.Packing | 1/10/50vial per box |
| 4.Indications | Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory tract Infections caused by S. pneumoniae (formerly D. pneumoniae). Staphylococcus aureus(penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria (Listeria monocytogenes, N. meningitidis). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcussp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella sp. respond to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptoccoccal endocarditis. Urinary Tract Infections caused by sensitve strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhosa (typhoid fever), other Salmonella sp., and Shigella sp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. |
| 1.Dosage | 1.5g: 1g ampicillin sodium + 500mg sulbactam sodium 0.75g: 500mg ampicillin sodium + 250mg sulbactam sodium |
| 2.Packing | 1/10/50vial per box |
| 1.Active ingredient | Piperacillin Sodium |
| 2.Dosage | 500mg, 1gram, 4gram |
| 3.Packing | 1/10/50vial per box |
| 1.Dosage | 4.5g: 4gram piperacillin sodium and 500mg tazobactam sodium 2.25g: 2gram piperacillin sodium and 250mg tazobactam sodium |
| 2.Packing | 1/10/50vial per box |
){kind=link}